Advertisement

Journal of Clinical Immunology

, Volume 22, Issue 2, pp 51–56 | Cite as

The IL-2/IL-15 Receptor Systems: Targets for Immunotherapy

  • Thomas A. Waldmann
Article

Abstract

Although interleukin-2 (IL-2) and -15 (IL-15) share two receptor subunits and many functions, at times they provide contrasting contributions to T-cell-mediated immune responses. IL-2, through its pivitol role in activation-induced cell death (AICD), is involved in peripheral tolerance through the elimination of self-reactive T cells. In contrast, in general IL-15 manifests antiapoptotic actions and inhibits IL-2-mediated AICD. IL-15 stimulates persistence of memory phenotype CD8+ T cells, whereas IL-2 inhibits their expression. Humanized monoclonal antibodies that recognize IL-2Rα, the private receptor for IL-2, are being employed to inhibit allograft rejection and to treat T-cell leukemia/lymphoma. Therapies directed toward inhibiting the actions of the inflammatory cytokine, IL-15, are proposed for an array of autoimmune disorders as well as diseases associated with the retrovirus human T-cell lymphotrophic virus 1.

Interleukin-2 interleukin 15 receptors monoclonal antibodies 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Baselga J, Norton L, Albanell J, et al: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831, 1998Google Scholar
  2. 2.
    Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma. Blood 90: 2188–2195, 1997Google Scholar
  3. 3.
    Waldmann TA: Multichain interleukin-2 receptor: A target for immunotherapy in lymphoma. J Natl Cancer Inst 81:914–923, 1989Google Scholar
  4. 4.
    Waldmann TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotrophic virus I induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72:1805–1816, 1988Google Scholar
  5. 5.
    Waldmann T A: The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727–732, 1986Google Scholar
  6. 6.
    Waldmann TA, White JD, Carrasquillo JA, et al: Radioimmunotherapy of IL-2R_-expressing adult T-cell leukemia with Yttrium-90 labeled anti-Tac. Blood 86:4063–4075, 1995Google Scholar
  7. 7.
    Lehky TJ, Levin M, Kubota R, et al: Reduction in HTLV-1 proviral load and spontaneous lymphoproliferation in HTLV-1-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac Ann Neurol 44:942–947, 1998Google Scholar
  8. 8.
    Nussenblatt RB, Fortin E, Schiffman R, et al: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac monoclonal antibody: A phase I/II clinical trial. Proc Natl Acad Sci USA 96: 7462–7466, 1999Google Scholar
  9. 9.
    Maeda M, Arima N, Daitoku Y, et al: Evidence for the interleukin-2 dependent expansion of leukemic cells in adult T cell leukemia. Blood 70:1407–1411, 1987Google Scholar
  10. 10.
    Tendler CL, Greenberg SJ, Blattner WA, et al: Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: Pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci USA 87:5218–5222, 1990Google Scholar
  11. 11.
    Burton JD, Bamford RN, Peters C, et al: A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 91:4935–4939, 1994Google Scholar
  12. 12.
    Bamford RN, Grant AJ, Burton JD, et al: The interleukin (IL) 2 receptor (?) chain is shared by IL-2 and a cytokine, provisionally designated IL-T that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci USA 91:4940–4944, 1994Google Scholar
  13. 13.
    Grabstein KH, Eisenman J, Shanebeck K, et al: Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 264:965–968, 1994Google Scholar
  14. 14.
    Lin JX, Migone TS, Tsang M, et al: The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2:331–339, 1995Google Scholar
  15. 15.
    Waldmann T, Tagaya Y: The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens, Annu Rev Immunol 17:19–49, 1999Google Scholar
  16. 16.
    Zhang X, Sun S, Hwang I, et al: Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15 Immunity 8:591–599, 1998Google Scholar
  17. 17.
    Ku CC, Murakami M, Sakamoto A, et al: Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288: 675–678, 2000Google Scholar
  18. 18.
    Marks-Konczalik J, Dubois S, Losi JM, et al: IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97:11445–11450, 2000Google Scholar
  19. 19.
    Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes; implications for immunotherapy. Immunity 14:105–110, 2001Google Scholar
  20. 20.
    Uchiyama, T, Broder S, Waldmann TA: A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol 126:1393–1397, 1981Google Scholar
  21. 21.
    Tsudo M, Kozak RW, Goldman CK, Waldmann TA: Demonstration of a non-Tac peptide that binds interleukin 2: A potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci USA 83:9694–9698, 1986Google Scholar
  22. 22.
    Kondo M, Takeshita T, Ishii N, et al: Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 262:1874–1877, 1993Google Scholar
  23. 23.
    Noguchi M, Nakamura Y, Russell SM, et al: Interleukin-2 receptor chain: A functional component of the interleukin-7 receptor. Science 262:1877–1880, 1993Google Scholar
  24. 24.
    Migone TS, Lin JX, Cereseto A, et al: Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1. Science 269:79–81, 1995Google Scholar
  25. 25.
    Carson WE, Fehniger TA, Haldar S, et al: A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937–943, 1997Google Scholar
  26. 26.
    Armitage RJ, Macduff BM, Eisenman J, et al: IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154:483–490, 1995Google Scholar
  27. 27.
    Leonardo MJ: Fas and the art of lymphocyte maintenance. J Exp Med 183:721–724, 1996Google Scholar
  28. 28.
    Azimi N, Nagai M, Jacobson S, Waldmann T: Interleukin 15 is an essential factor for the persistence of the Tax-specific CD8 cells in HAM/TSP patients. Proc Natl Acad Sci USA 98:14559–14564. 2001Google Scholar
  29. 29.
    Sadlack B, Kuhn R, Schorle H, et al: Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and-4. Eur J Immunol 24:281–284, 1994Google Scholar
  30. 30.
    Willerford DM, Chen J, Ferry, JA, et al: Interleukin-2 receptor ? chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521–530, 1995Google Scholar
  31. 31.
    Kennedy MK, Glaccum M, Brown SN, et al: Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 191:771–780, 2000Google Scholar
  32. 32.
    Lodolce JP, Boone DL, Chai S, et al: IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669–676, 1998Google Scholar
  33. 33.
    Chiron Corporation Proleukin. Physicians Desk Reference: 894–897, 1999Google Scholar
  34. 34.
    Shevach EM, Certified Professionals: CD4_ CD25_ Suppressor T cells. J Exp Med 193:F41–F45, 2001Google Scholar
  35. 35.
    Siekevitz M, Feinberg MB, Holbrook N, et al: Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the transactivator (tat) gene product of human T-cell leukemia virus Type I. Proc Natl Acad Sci USA 84:5389–5393, 1987Google Scholar
  36. 36.
    Azimi N, Brown K, Bamford RN, et al: Human T-cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-κ? site. Proc Natl Acad Sci USA 95:2452–2457, 1998Google Scholar
  37. 37.
    Mariner JM, Lantz V, Waldmann TA, Azimi N: Human T cell lymphotropic virus type I Tax protein activates interleukin 15 receptor alpha gene expression through the action of NF-κ?. J Immunol 166:2602–2609, 2001Google Scholar
  38. 38.
    Phillips KE, Herring B, Wilson LA, et al: IL-2R-directed monoclonal antibodies provide effective therapy in a murine model of? adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2R_ interaction. Cancer Res 60:6977–6984, 2000Google Scholar
  39. 39.
    Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446, 2000Google Scholar
  40. 40.
    Queen C, Schneider WP, Selick HE, et al: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029–10033, 1989Google Scholar
  41. 41.
    Junghans RP, Waldmann TA, Landolfi NF, et al: Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50:1495–1502, 1990Google Scholar
  42. 42.
    Vincenti F, Kirkman R, Light S, et al: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. New Engl J Med 338:161–165, 1998Google Scholar
  43. 43.
    Nashan B, Moore R, Amlot P, et al: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recepients. CHIB 201 International Study Group. Lancet 350:1193–1198, 1997Google Scholar
  44. 44.
    Bamford RN, DeFilippis AP, Azimi N, et al: The 5′ untranslated region, signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its multifaceted translational control. J Immunol 160:4418–4426, 1998Google Scholar
  45. 45.
    Ogasawara K, Hida S, Azimi N, et al: Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391:700–703, 1998Google Scholar
  46. 46.
    Ohteki T, Yoshida H, Matsuyama T, et al: The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J Exp Med 187:967–972, 1998Google Scholar
  47. 47.
    Azimi N, Jacobson S, Leist T, Waldmann TA: Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: Implications for therapy with a monoclonal antibody directed to the IL-2/15R? receptor. J Immunol 163:4064–4072, 1999Google Scholar
  48. 48.
    Ruchatz H, Leung BP, Wei XQ, et al: Soluble IL-15 receptor _-chain administration prevents murine collagen-induced arthritis: A role for IL-15 in development of antigen-induced immunopathology. J Immunol 160:5654–5660, 1998Google Scholar
  49. 49.
    Kim YS, Maslinski W, Zheng XX, et al: Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fcγ2a protein blocks delayed-type hypersensitivity. J. Immunol 160:5742–5748, 1998Google Scholar
  50. 50.
    Tinubu SA, Hakimi J, Kondas JA: Humanized antibody directed to the IL-2 receptor ?-chain prolongs primate cardiac allograft survival. J Immunol 153:4330–4338, 1994Google Scholar
  51. 51.
    Hakimi J, Ha VC, Lin P, et al: Humanized Mik? 1, a humanized antibody to the IL-2 receptor ?-chain that acts synergistically with humanized anti-Tac. J Immunol 151:1075–1085, 1993Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • Thomas A. Waldmann
    • 1
  1. 1.Metabolism Branch, Center for Cancer ResearchNational Cancer InstituteBethesdaUSA

Personalised recommendations